Literature DB >> 18726069

Serum amyloid A: an acute-phase protein involved in tumour pathogenesis.

E Malle1, S Sodin-Semrl, A Kovacevic.   

Abstract

The synthesis of acute-phase protein serum amyloid A (SAA) is largely regulated by inflammation- associated cytokines and a high concentration of circulating SAA may represent an ideal marker for acute and chronic inflammatory diseases. However, SAA is also synthesized in extrahepatic tissues, e.g. human carcinoma metastases and cancer cell lines. An increasing body of in vitro data supports the concept of involvement of SAA in carcinogenesis and neoplastic diseases. Accumulating evidence suggests that SAA might be included in a group of biomarkers to detect a pattern of physiological events that reflect the growth of malignancy and host response. This review is meant to provide a broad overview of the many ways that SAA could contribute to tumour development, and accelerate tumour progression and metastasis, and to gain a better understanding of this acute-phase reactant as a possible link between chronic inflammation and neoplasia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18726069      PMCID: PMC4864400          DOI: 10.1007/s00018-008-8321-x

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  198 in total

1.  Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis.

Authors:  S D Yan; H Zhu; A Zhu; A Golabek; H Du; A Roher; J Yu; C Soto; A M Schmidt; D Stern; M Kindy
Journal:  Nat Med       Date:  2000-06       Impact factor: 53.440

2.  Targeted protein quantitation and profiling using PVDF affinity probe and MALDI-TOF MS.

Authors:  Shu-Hua Chen; Hsin-Kai Liao; Chih-Yang Chang; Chiun-Gung Juo; Jenn-Han Chen; Sunney I Chan; Yu-Ju Chen
Journal:  Proteomics       Date:  2007-09       Impact factor: 3.984

Review 3.  Advancing cancer biotherapy with proteomics.

Authors:  David F Stroncek; Christine Burns; Brian M Martin; Leonardo Rossi; Francesco M Marincola; Monica C Panelli
Journal:  J Immunother       Date:  2005 May-Jun       Impact factor: 4.456

4.  A model for p53-induced apoptosis.

Authors:  K Polyak; Y Xia; J L Zweier; K W Kinzler; B Vogelstein
Journal:  Nature       Date:  1997-09-18       Impact factor: 49.962

5.  Assessment of systemic inflammation markers to differentiate a stable from a deteriorating clinical course in patients with febrile neutropenia.

Authors:  Lennart Persson; Bo Söderquist; Per Engervall; Tomas Vikerfors; Lars-Olof Hansson; Ulf Tidefelt
Journal:  Eur J Haematol       Date:  2005-04       Impact factor: 2.997

6.  Recombinant human serum amyloid A (apoSAAp) binds cholesterol and modulates cholesterol flux.

Authors:  J S Liang; J D Sipe
Journal:  J Lipid Res       Date:  1995-01       Impact factor: 5.922

Review 7.  Serum amyloid A (SAA): an acute phase protein and apolipoprotein.

Authors:  E Malle; A Steinmetz; J G Raynes
Journal:  Atherosclerosis       Date:  1993-09       Impact factor: 5.162

8.  Biological and biochemical characterization of an interleukin 1-like factor from rat C6 glioma cells.

Authors:  A Fontana; K P McAdam; F Kristensen; E Weber
Journal:  Eur J Immunol       Date:  1983-08       Impact factor: 5.532

9.  Is serum amyloid A an endogenous TLR4 agonist?

Authors:  Silvana Sandri; Dunia Rodriguez; Eliane Gomes; Hugo Pequeno Monteiro; Momtchilo Russo; Ana Campa
Journal:  J Leukoc Biol       Date:  2008-02-05       Impact factor: 4.962

10.  Serum proteome analysis for profiling protein markers associated with carcinogenesis and lymph node metastasis in nasopharyngeal carcinoma.

Authors:  Qiulin Liao; Liang Zhao; Xiaodong Chen; Yongjian Deng; Yanqing Ding
Journal:  Clin Exp Metastasis       Date:  2008-03-21       Impact factor: 5.150

View more
  76 in total

1.  Identification of potential serum biomarkers for Wilms tumor after excluding confounding effects of common systemic inflammatory factors.

Authors:  Jiaxiang Wang; Lei Wang; Da Zhang; Yuxia Fan; Zhankui Jia; Pan Qin; Jiekai Yu; Shu Zheng; Fuquan Yang
Journal:  Mol Biol Rep       Date:  2011-12-08       Impact factor: 2.316

2.  An integrated proteomic approach to identifying circulating biomarkers in high-risk neuroblastoma and their potential in relapse monitoring.

Authors:  Rachel A Egler; Yiting Li; Tu Anh T Dang; Tricia L Peters; Eastwood Leung; Shixia Huang; Heidi V Russell; Hao Liu; Tsz-Kwong Man
Journal:  Proteomics Clin Appl       Date:  2011-09-07       Impact factor: 3.494

3.  Serum amyloid A1 isoforms display different efficacy at Toll-like receptor 2 and formyl peptide receptor 2.

Authors:  Mingjie Chen; Huibing Zhou; Ni Cheng; Feng Qian; Richard D Ye
Journal:  Immunobiology       Date:  2014-08-10       Impact factor: 3.144

4.  Proteomic analysis of haptoglobin and amyloid A protein levels in patients with vivax malaria.

Authors:  Young Yil Bahk; Byoung-Kuk Na; Shin-Hyeong Cho; Jung-Yeon Kim; Kook-Jin Lim; Tong-Soo Kim
Journal:  Korean J Parasitol       Date:  2010-09-16       Impact factor: 1.341

5.  Identification of p130Cas/ErbB2-dependent invasive signatures in transformed mammary epithelial cells.

Authors:  Alessandra Pincini; Giusy Tornillo; Francesca Orso; Marianna Sciortino; Brigitte Bisaro; Maria Del Pilar Camacho Leal; Antonio Lembo; Maria Felice Brizzi; Emilia Turco; Cristiano De Pittà; Paolo Provero; Enzo Medico; Paola Defilippi; Daniela Taverna; Sara Cabodi
Journal:  Cell Cycle       Date:  2013-06-28       Impact factor: 4.534

6.  Evaluation of preoperative serum markers for individual patient prognosis in stage I-III rectal cancer.

Authors:  Clemens Giessen; Dorothea Nagel; Maria Glas; Fritz Spelsberg; Ulla Lau-Werner; Dominik Paul Modest; Marlies Michl; Volker Heinemann; Petra Stieber; Christoph Schulz
Journal:  Tumour Biol       Date:  2014-07-17

7.  Pathogenic serum amyloid A 1.1 shows a long oligomer-rich fibrillation lag phase contrary to the highly amyloidogenic non-pathogenic SAA2.2.

Authors:  Saipraveen Srinivasan; Sanket Patke; Yun Wang; Zhuqiu Ye; Jeffrey Litt; Sunit K Srivastava; Maria M Lopez; Dmitry Kurouski; Igor K Lednev; Ravi S Kane; Wilfredo Colón
Journal:  J Biol Chem       Date:  2012-12-05       Impact factor: 5.157

8.  Serum amyloid A is elevated in the serum of lung cancer patients with poor prognosis.

Authors:  W C S Cho; T T Yip; W W Cheng; J S K Au
Journal:  Br J Cancer       Date:  2010-05-25       Impact factor: 7.640

9.  Ah receptor represses acute-phase response gene expression without binding to its cognate response element.

Authors:  Rushang D Patel; Iain A Murray; Colin A Flaveny; Ann Kusnadi; Gary H Perdew
Journal:  Lab Invest       Date:  2009-03-30       Impact factor: 5.662

10.  Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer.

Authors:  E Cocco; S Bellone; K El-Sahwi; M Cargnelutti; F Casagrande; N Buza; F A Tavassoli; E R Siegel; I Visintin; E Ratner; D-A Silasi; M Azodi; P E Schwartz; T J Rutherford; S Pecorelli; A D Santin
Journal:  Br J Cancer       Date:  2009-06-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.